PAR. SP, page-725

totally understand Slura. I’ve read and listened and re-listened and re-read paradigms releases over and over and over again.

Rennie knows he needs deals.

We are at the pointy end of the scenic route, now.

He has stated many times that he wants to progress the asset as far as he can to maximise the deal outcome for shareholders. Clearly he wants to get the asset through this next batch of regulatory meetings.

Paul’s efforts leading into the 2023 cap raise were poor as I view this through the lens that, he was a chairman at NSB at the time (distraction? Poor optics! Filling his back pocket) and he made an assumption the market would buy on the back of his “we have found the DMOAD holy grail” and it didn’t. Oh and China didn’t deal….. then.

We aren’t privy to non binding offers or discussions. There are statements and there are clues things are moving along there and I’m VERY glad we are sitting on the datasets we have generated so far.

I don’t know which way this goes but, like you…. I’ve been on the scenic route for years now… and in a weak moment I do nibble on more. However I’m as confused as the next shareholder about where this MPS data is.

Lastly, I do believe we will get good outcomes from the regulatory meeting upcoming and that will allow our collective focus to move to chances of us getting through a phase 3 trial with our preferred dose and therefore a high probability deals will be written shortly after.